Skip to main content

Advertisement

Log in

Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated demyelinating neuropathy. It is the most common treatable acquired polyneuropathy and represents a significant number of initially undiagnosed neuropathy patients. This article reviews the common clinical, laboratory, and electrodiagnostic features of CIDP. In addition, current areas of uncertainty are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Dyck PJ, Lais AC, Ohta M, et al.: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975, 50:621–637.

    PubMed  CAS  Google Scholar 

  2. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR: Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989, 46:878–884.

    PubMed  CAS  Google Scholar 

  3. Hattori N, Misu K, Koike H, et al.: Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000, 184:57–63.

    Article  Google Scholar 

  4. Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997, 48:321–328.

    PubMed  CAS  Google Scholar 

  5. Sabatelli M, Madia F, Mignogna T, et al.: Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol 2001, 248:772–777.

    Article  PubMed  CAS  Google Scholar 

  6. Prineas JW, McLeod JG: Chronic relapsing polyneuritis. J Neurol Sci 1976, 27:427–458.

    Article  PubMed  CAS  Google Scholar 

  7. Sakakibara R, Hattori T, Kuwabara S, et al.: Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 50:1179–1182.

    PubMed  CAS  Google Scholar 

  8. van der Meche FG, van Doorn PA: Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995, 37(suppl 1):S14-S31.

    Article  PubMed  Google Scholar 

  9. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41:617–618.

    Google Scholar 

  10. Dalakas M, Houff SA, Engel WK, Madden DL, Sever JL: CSF "monoclonal" bands in chronic relapsing polyneuropathy. Neurology 1980, 30:864–867.

    PubMed  CAS  Google Scholar 

  11. Kissel JT, Mendell JR: Neuropathies associated with monoclonal proteins. Neuromusc Disord 1995, 6:3–18.

    Article  Google Scholar 

  12. Albers JW, Kelly JJ: Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989, 12:435–451.

    Article  PubMed  CAS  Google Scholar 

  13. Bromberg MB: Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991, 14:968–976.

    Article  PubMed  CAS  Google Scholar 

  14. Rotta FT, Sussman AT, Bradley WG, et al.: The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000, 173:129–139.

    Article  PubMed  CAS  Google Scholar 

  15. Rhee EK, England JD, Sumner AJ: A computer simulation of conduction block: effects produced by actual block versus interphase cancellation. Ann Neurol 1990, 28:146–156.

    Article  PubMed  CAS  Google Scholar 

  16. Oh SJ, Kim DE, Koruoglu AR: What is the best diagnostic index of conduction block and temporal dispersion. Muscle Nerve 1994, 17:489–493.

    Article  PubMed  CAS  Google Scholar 

  17. Cornblath DR, Sumner AJ, Daube J, et al.: Conduction block in clinical practice. Muscle Nerve 1991, 14:869–871.

    Article  PubMed  CAS  Google Scholar 

  18. Olney RK: Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve 1999, 22(suppl 8):S225-S229.

    Google Scholar 

  19. Molenaar DS, Vermeulen M, de Haan R: Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1998, 64:84–89.

    Article  PubMed  CAS  Google Scholar 

  20. Bosboom WM, Van den Berg LH, Franssen H, et al.: Diagnostic value of sural demyelination in chronic inflammatory demyelinating polyneuropathy. Brain 2001, 124:2427–2438.

    Article  PubMed  CAS  Google Scholar 

  21. Dyck PJ, O’Brien PC, Oviatt KF, et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136–141.

    Article  PubMed  CAS  Google Scholar 

  22. Dyck PJ, Daube J, O’Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461–465.

    Article  PubMed  CAS  Google Scholar 

  23. Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055–1066.

    Article  PubMed  Google Scholar 

  24. Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebocontrolled, cross-over study. Brain 1996, 119:1067–1077.

    Article  PubMed  Google Scholar 

  25. Mendell JR, Barohn RJ, Freimer ML, et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56:445–449. In contrast to the chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients studied by Hahn et al. [24], the subjects of this trial had never been previously treated with any immunemodulating therapies. This study thus demonstrated that intravenous immunoglobulin can be an effective initial therapy for CIDP.

    PubMed  CAS  Google Scholar 

  26. Hughes R, Bensa S, Willison H, et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195–201.

    Article  PubMed  CAS  Google Scholar 

  27. Dyck PJ, O’Brien P, Swanson C, Low P, Daube J: Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1985, 35:1173–1176.

    PubMed  CAS  Google Scholar 

  28. Barnett MH, Pollard JD, Davies L, McLeod JG: Cyclosporine A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998, 21:454–460.

    Article  PubMed  CAS  Google Scholar 

  29. Hodgkinson SJ, Pollard JD, McLeod JG: Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 1990, 53:327–330.

    PubMed  CAS  Google Scholar 

  30. Good JL, Chehrenama M, Mayer RF, Koski CL: Pulsed cyclophosphamide in chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 51:1735–1738.

    PubMed  CAS  Google Scholar 

  31. Brannagan TH, Pradham A, Heiman-Patterson T, et al.: High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002, 58:1856–1858.

    PubMed  CAS  Google Scholar 

  32. Sabatelli M, Mignogna T, Lippi G, et al.: Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1995, 58:638–639.

    PubMed  CAS  Google Scholar 

  33. Gorson KC, Ropper AH, Clark BD, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998, 50:84–87.

    PubMed  CAS  Google Scholar 

  34. Mowzoon N, Sussman A, Bradley WG: Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001, 185:119–122.

    Article  PubMed  CAS  Google Scholar 

  35. Chaudhry V, Cornblath DR, Griffin JW, O’Brien R, Drachman DB: Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001, 56:94–96.

    PubMed  CAS  Google Scholar 

  36. Saperstein DS, Katz JS, Amato AA, Barohn RJ: Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001, 24:311–324.

    Article  PubMed  CAS  Google Scholar 

  37. Kyle RA, Dyck PJ: Neuropathy associated with the monoclonal gammopathies. In Peripheral Neuropathy, edn 3. Edited by Dyck PJ, Thomas PK, Griffin JW, Low PA, Podulso JF. Philadelphia: WB Saunders; 1993:1275–1287.

    Google Scholar 

  38. Katz JS, Saperstein DS, Gronseth GS, Amato AA, Barohn RJ: Distal acquired demyelinating symmetrical neuropathy. Neurology 2000, 54:615–620.

    PubMed  CAS  Google Scholar 

  39. Simmons Z, Albers JW, Bromberg MB, Feldman EL: Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993, 43:2202–2209.

    PubMed  CAS  Google Scholar 

  40. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G: Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000, 123:710–717.

    Article  PubMed  Google Scholar 

  41. Sharma KR, Cross J, Farronay O, et al.: Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002, 59:758–765.

    Article  PubMed  Google Scholar 

  42. Gorson KC, Ropper AH, Adelman LS, Weinberg DH: Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000, 23:37–43.

    Article  PubMed  CAS  Google Scholar 

  43. Sharma KR, Cross J, Ayyar DR, Martinez-Arizala A, Bradley WG: Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002, 59:751–757.

    Article  PubMed  Google Scholar 

  44. Wilson JR, Park Y, Fisher MR: Electrodiagnostic criteria in CIDP: comparison with diabetic neuropathy. Electromyogr Clin Neurophysiol 2000, 40:181–185.

    PubMed  CAS  Google Scholar 

  45. Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR: The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later. Arch Neurol 1991, 48:1130–1135.

    PubMed  CAS  Google Scholar 

  46. Abu-Shakra SR, Cornblath DR, Avila OL, et al.: Conduction block in diabetic neuropathy. Muscle Nerve 1991, 14:858–862.

    Article  PubMed  CAS  Google Scholar 

  47. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR: Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993, 50:137–139.

    PubMed  CAS  Google Scholar 

  48. Nicolas G, Maisonobe T, Le Forestier N, Leger JM, Bouche P: Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2002, 25:26–30.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saperstein, D.S., Barohn, R.J. Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy. Curr Neurol Neurosci Rep 3, 57–63 (2003). https://doi.org/10.1007/s11910-003-0039-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-003-0039-4

Keywords

Navigation